Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression

Table 1 MiRNAs that were differentially expressed between LVSI-positive and LVSI-negative ovarian cancer tissues

Downregulated miRNA	LVSI(+)/LVSI(−) Fold change	P value	Adjusted P value	Upregulated miRNA	LVSI(+)/LVSI(−) Fold change	P value	Adjusted P value
hsa-miR-25	0.778	< 0.001	0.025	hsa-miR-142-5p	1.651	< 0.001	0.025
hsa-miR-96	0.614	0.002	0.143	hsa-miR-22	1.516	< 0.001	0.063
hsa-miR-183	0.700	0.004	0.161	hsa-miR-142-3p	1.600	< 0.001	0.065
hsa-miR-514	0.625	0.008	0.180	hsa-miR-21	1.272	< 0.001	0.065
hsa-miR-218	0.716	0.007	0.180	hsa-let-7b	1.334	0.001	0.082
hsa-miR-335	0.770	0.008	0.180	hsa-miR-21^*	1.426	0.002	0.143
hsa-miR-509-5p	0.742	0.013	0.204	hsa-miR-199a-5p	1.444	0.005	0.180
hsa-miR-375	0.793	0.012	0.204	hsa-miR-150	1.388	0.004	0.180
hsa-miR-26b	0.758	0.015	0.222	hsa-miR-483-5p	1.324	0.008	0.180
hsa-miR-200a	0.747	0.016	0.225	hsa-miR-202	1.277	0.005	0.180
hsa-miR-125b	0.785	0.018	0.229	hsa-miR-199b-3p	1.373	0.012	0.204
hsa-miR-509-3p	0.719	0.026	0.276	hsa-miR-214	1.360	0.012	0.204
hsa-let-7e	0.793	0.029	0.284	hsa-miR-638	1.338	0.014	0.212
hsa-miR-507	0.782	0.039	0.312	hsa-miR-1225-5p	1.345	0.018	0.229
hsa-miR-99a	0.790	0.040	0.315	hsa-miR-188-5p	1.269	0.017	0.229
hsa-miR-509-3-5p	0.730	0.045	0.323	hsa-miR-222	1.265	0.024	0.267
				hsa-miR-144	1.355	0.028	0.284
				hsa-miR-223	1.330	0.030	0.286

ISSN: 1757-2215